Paperpal Prime Logo

Pharmacogenomics Journal : Impact Factor & More

eISSN: 1473-1150pISSN: 1470-269X

Key Metrics

CiteScore
6.5
H-Index
93
Impact Factor
< 5
SJR
Q2Genetics
SNIP
1
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Pharmacogenomics Journal

Pharmacogenomics Journal Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher SPRINGERNATURE
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Pharmacogenomics Journal ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Check your researchless than 30 sec
Free Report

Recently Published Papers in Pharmacogenomics Journal

Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation.
  • 30 Jul 2026
  • The pharmacogenomics journal
Finasteride, pharmacogenomics, and suicide risk: a public health concern.
  • 9 Jun 2026
  • The pharmacogenomics journal
Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.
  • 6 Jun 2026
  • The pharmacogenomics journal
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.
  • 25 May 2026
  • The pharmacogenomics journal
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.
  • 24 Apr 2026
  • The pharmacogenomics journal
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population.
  • 20 Apr 2026
  • The pharmacogenomics journal
Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation.
  • 30 Jul 2026
  • The pharmacogenomics journal
Finasteride, pharmacogenomics, and suicide risk: a public health concern.
  • 9 Jun 2026
  • The pharmacogenomics journal
Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.
  • 6 Jun 2026
  • The pharmacogenomics journal
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China.
  • 25 May 2026
  • The pharmacogenomics journal
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.
  • 24 Apr 2026
  • The pharmacogenomics journal
Cost-effectiveness of genotype-guided acenocoumarol therapy in atrial fibrillation: a pharmacogenomic simulation study in the chilean population.
  • 20 Apr 2026
  • The pharmacogenomics journal
View all papers for this journal

FAQs on Pharmacogenomics Journal

Global Journal Library:

Paperpal Prime logo

Cactus Communications Services Pte Ltd
20 McCallum Street, #19-01, Tokio Marine Centre, Singapore 069046

We are with you every step of the way as you achieve your dreams - publication, everything that precedes it, and everything that comes after. You are much more than your last research project. It’s time you got more.

Instagram icon

USEFUL LINKS

EXCITED ABOUT RESEARCHER.LIFE?

We are always looking for inspiration, feedback, and collaborators

Write to us

Copyright 2026 Cactus Communications. All rights reserved.

Privacy PolicyCookies PolicyTerms of UseCareers
Check if your manuscript is a good match for
undefined

Upload your manuscript to get recommendations of journals
that have published papers similar to your manuscript


word doc icon
Drag and drop your file here
We accept manuscripts in English. File format: .doc and .docx | Maximum size: 10 MB | Word count: 200-300,000 words | File length: less than 100 pages

Do not have a manuscript right now? Use an abstract or summary

Your document is 100% secure & confidential

We use 256-bit encryption for total security and
ISO/IEC 27001:2013 Certified

What all does the report include
01. Degree of Match
02. Common Topics
03. Additional
Recommendations